BioCardia (BCDA), Cuorips (4894.T): Japan Prices Cardiac Cell Therapy

Between March and August 2026, Cuorips (4894.T) confirmed in a company press release that its iPS-derived cardiomyocyte therapy had received conditional, time-limited marketing approval in Japan [1]. On its August 12 earnings call, BioCardia (BCDA) said that same product, in the same indication, was confirmed for reimbursement in July at about $326,000 per treatment, and that Japan's regulator considers the results of BioCardia's completed US trials credible [2].

---

A pathway that grants approval on a handful of treated patients

Cardiac cell therapy transplants laboratory-grown cells onto the heart to treat ischemic heart failure — heart muscle that has lost contractile strength after prolonged poor blood supply — in patients whose drug options are exhausted. Bringing such a product to market normally requires a completed large randomized controlled trial followed by years of review. Japan offers another route. Conditional, time-limited approval grants marketing authorization on a very small number of treated patients, in exchange for a mandatory post-marketing study and a seven-year clock: if efficacy is not confirmed inside that window, the approval is withdrawn [3].

Approval by itself is not what changes the economics. In Japan the reimbursed price is set by the Central Social Insurance Medical Council under the Ministry of Health, Labour and Welfare using a cost-calculation method, and the result is a public number [4]. Every later product in the category negotiates against that number, so the first product through the process effectively sets the reference price for the ones behind it.

---

Two printed prices and a sixteen-fold gap

Japan approved two iPS-derived regenerative medicine products on the same day, March 6, 2026. ReHeart, for severe ischemic heart failure, had been transplanted into eight patients at the time of approval; the other product had seven [3]. On July 22 the health ministry set ReHeart's price at ¥53.2 million, making it the second iPS-derived product covered by Japanese public insurance [4]. The earlier product, Amchepry, was priced at ¥55.3 million, or $350,600, with coverage starting May 20 [5].

That price sits an order of magnitude above current US practice. When BioCardia sized the Japanese opportunity, its reference point was a US procedure fee of roughly $20,000, against an estimated 300,000 Japanese ischemic heart failure patients and about 20,000 reachable initially [6]. Priced as a cell product in Japan, a single treatment carries about sixteen times that US reference figure.

BioCardia has reordered its own filings around this. It said the Pharmaceuticals and Medical Devices Agency found the outcomes of its completed US CardiAMP trials credible, and that the remaining requests are documentation — evidence that enrolled patients were on guideline-directed medical therapy and were not eligible for revascularization — with approval expected roughly 12 months after submission [2].

---

The entry point for first revenue moved to Japan's health ministry

For companies developing cardiac cell therapy, the institution that decides when they can book a first product sale has changed sides. The evidence bar and the price are settled inside one process, and the price is public, so the cheapest route to first revenue for a small US sponsor shifts from running a second US pivotal trial to preparing a Japanese marketing application. BioCardia said the two publicly traded Japanese companies advancing cardiac cell therapies each carry a market capitalization of about $250 million, while it has performed more than 20 times as many clinical procedures as both of them combined [2].

Several boundaries limit that reading. A conditional approval can be taken back: Terumo's HeartSheet won conditional approval in the same indication in 2015 on a trial of seven patients, its post-marketing study failed to demonstrate efficacy, and sales ended on July 20, 2024 [7]. The price itself is being cut — the Central Social Insurance Medical Council endorsed halving the profit coefficient for conditionally approved regenerative medicines in November 2025, effective April 2026 [8]. The market has so far priced this in Tokyo: between July 17 and August 13, 2026, Cuorips rose 19.5% and Heartseed rose 29.8%, while BioCardia rose 6.6% and fell 5.6% on the day of its disclosure [9]. BioCardia has also said its full-cohort statistics did not reach significance and that it expects approval in the elevated NT-proBNP subgroup [10]. Two things can be checked later: whether BioCardia's Japanese submission is actually filed, and whether ReHeart produces sales now that it carries a price.

---

Which companies this change affects:

• Heartseed (219A.T): It is developing an iPS-derived cardiomyocyte therapy for severe ischemic heart failure, the same indication [11], so when it reaches the pricing step the number it argues against is ReHeart's ¥53.2 million.
• Healios (4593.T): It develops a cell therapy for acute respiratory distress syndrome and said on August 13, 2026 that it will pursue conditional, time-limited approval without waiting for the results of its REVIVE-ARDS trial [12], which shows the pathway is a general rule for regenerative medicine products rather than something specific to the heart.

---

Sources

[1] Cuorips · World's First iPSC-Derived Cardiomyocyte Therapy for Heart Failure Receives Conditional Approval in Japan · 2026-03-06 · company press release · https://www.cuorips.co.jp/news-en/20260306

[2] Drillr · BioCardia (BCDA) · 2026-08-12 · FY2026 Q2 earnings call

"In Japan, another cell therapy for the same indication was approved in March of this year. And has received confirmation that they have been approved for reimbursement in July at $326 thousand per treatment. This underscores the need recognized in Japan for such a therapy that cardiac cell therapy is now a real market in Japan and that cardiac cell therapy has potential to be an enormously valuable therapy."

[3] Science Japan (JST) · Japan gives first-ever approval to regenerative medicine products using iPS cells · 2026-05-18 · news report · https://sj.jst.go.jp/stories/2026/s0518-01p.html

[4] Nikkei · MHLW sets ReHeart's official price at ¥53.2 million · 2026-07-22 · news report · https://www.nikkei.com/article/DGXZQOUA223Q80S6A720C2000000/

[5] The Japan Times · Sumitomo Pharma's Amchepry approved for public insurance coverage · 2026-05-13 · news report · https://www.japantimes.co.jp/news/2026/05/13/japan/science-health/ips-parkinsons-disease/

[6] Drillr · BioCardia (BCDA) · 2026-05-15 · FY2026 Q1 earnings call

[7] PHARMA JAPAN · Terumo to End Sale of HeartSheet after Panel's Thumbs-Down · 2024-07-20 · news report · https://pj.jiho.jp/article/251362

[8] PHARMA JAPAN · Chuikyo Backs Halving Profit Coefficient for Conditionally Approved Regenerative Medicines · 2025-11-13 · news report · https://pj.jiho.jp/article/254570

[9] Drillr · price_volume_history · 2026-08-13 · daily price bars

[10] Drillr · BioCardia (BCDA) · 2026-03-24 · FY2025 Q4 earnings call

[11] Drillr · company_search · 2026-08-13 · cardiac cell therapy developer screen

[12] Kabutan · Healios (4593.T) to file for conditional approval without waiting for REVIVE-ARDS results · 2026-08-13 · news report · https://s.kabutan.jp/news/n202608130878/

This is only meant to surface industry changes and companies you may have overlooked - it is not a stock recommendation.